Efficacy and safety of evolocumab in patients on high- vs moderate-intensity background statin therapy
Soran, H, Lira, A, Dent, R, Bridges, I, Somaratne, R, Koren, M
Published in Atherosclerosis (01.09.2016)
Published in Atherosclerosis (01.09.2016)
Get full text
Journal Article
Evolocumab use in Greece is associated with early and sustainable reductions in low-density cholesterol (LDL-C) and high persistence to therapy: Results from the Greek cohort analysis of the observational HEYMANS study
Vlachopoulos, C., Massia, D., Kochiadakis, G., Kolovou, G., Patsilinakos, S., Bridges, I., Sibartie, M., Dhalwani, N.N., Liberopoulos, E., Ray, K.K.
Published in Hellenic journal of cardiology (01.11.2023)
Published in Hellenic journal of cardiology (01.11.2023)
Get full text
Journal Article
The efficacy of evolocumab and other lipid-lowering therapies (LLT) for the management of low density lipoprotein cholesterol (LDL-C): a systematic review and network meta-analysis (NMA)
Worthy, G, Gandra, S.R, Bridges, I, Worth, G, Dent, R, Cheng, L.I, Forbes, C, Deshpande, S, Ross, J, Kleijnen, J, Stroes, E.S.G
Published in Atherosclerosis (01.09.2016)
Published in Atherosclerosis (01.09.2016)
Get full text
Journal Article
EFFICACY AND SAFETY OF THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH MIXED HYPERLIPIDEMIA
Rosenson, R.S, Jacobson, T.A, Priess, D, Djedjos, C, Dent, R, Bridges, I, Pellacani, A, Miller, M
Published in Canadian journal of cardiology (01.10.2015)
Published in Canadian journal of cardiology (01.10.2015)
Get full text
Journal Article
An observational study of the effectiveness of darbepoetin alpha administered in dialysis patients once every 2 weeks for 12 months
Rottembourg, J B, Bridges, I, Pronai, W, Feriani, M, McMahon, L P, De Meester, J M J, Farouk, M, Molemans, B
Published in Clinical nephrology (01.03.2011)
Published in Clinical nephrology (01.03.2011)
Get more information
Journal Article
Intercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients
DeFrancisco, A L M, Macdougall, I C, Carrera, F, Braun, J, Bárány, P, Bridges, I, Wheeler, T, Tran, D, Dietrich, A
Published in Clinical nephrology (01.04.2009)
Published in Clinical nephrology (01.04.2009)
Get more information
Journal Article
Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study
Blaha, V, Margoczy, R, Petrov, I, Postadzhiyan, A, Raslova, K, Rosolova, H, Bridges, I, Dhalwani, N N, Zachlederova, M, Ray, K K
Published in European Cardiology Review (ECR) (2023)
Published in European Cardiology Review (ECR) (2023)
Get full text
Journal Article
Safety of very low LDL-C levels with evolocumab: An analysis from the pan-European observational HEYMANS study
Ray, K., Perrone-Filardi, P., Ebenbichler, C., Vogt, A., Bridges, I., Sibartie, M., Dhalwani, N.
Published in Atherosclerosis (01.08.2023)
Published in Atherosclerosis (01.08.2023)
Get full text
Journal Article
Franchising & Distribution Currents
Shelley, Kevin M., Bridges, Emily I., Morris, Marlén Cortez
Published in Franchise law journal (22.06.2019)
Get full text
Published in Franchise law journal (22.06.2019)
Journal Article
Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry
Ray, K K, Perrone-Filardi, P, Ebenbichler, C, Vogt, A, Bridges, I, Sibartie, M, Dhalwani, N N
Published in European heart journal (03.10.2022)
Published in European heart journal (03.10.2022)
Get full text
Journal Article
Evolocumab use and LDL-C lowering in a cohort of european patients with familial hypercholesterolemia (FH) - Results from the Heymans study
Sibartie, M., Dhalwani, N., Bridges, I., Ebenbichler, C., Filardi, P. Peronne, Vogt, A., Bruckert, E.
Published in Atherosclerosis (01.08.2021)
Published in Atherosclerosis (01.08.2021)
Get full text
Journal Article
Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study
Ray, K.K, Bruckert, E, Van Hout, B, Feudjo Tepie, M, Bridges, I, Sibartie, M
Published in European heart journal (01.11.2020)
Published in European heart journal (01.11.2020)
Get full text
Journal Article
What potential risk reduction could be achieved with evolocumab treatment? A simulation based on observational data from a cohort of users in 10 European countries
Ray, K.K, Bridges, I, Bruckert, E, Van Hout, B, Sibartie, M, Villa, G
Published in European heart journal (01.11.2020)
Published in European heart journal (01.11.2020)
Get full text
Journal Article
Final results from the pan-European observational heymans study suggest a mismatch between guidelines and PCSK9i reimbursement criteria
Ray, K.K., Bruckert, E., Perrone-Filardi, P., Ebenbichler, C., Vogt, A., Bridges, I., Sibartie, M., Dhalwani, N.
Published in Atherosclerosis (01.08.2022)
Published in Atherosclerosis (01.08.2022)
Get full text
Journal Article
Baseline characteristics of bulgarian patients prescribed evolocumab in clinical practice
Petkova, R., Postadzhiyan, A., Petrov, I., Tisheva, S., Borizanova-Petkova, A., Bridges, I.
Published in Atherosclerosis (01.12.2020)
Published in Atherosclerosis (01.12.2020)
Get full text
Journal Article
Potential cardiovascular risk reduction with evolocumab in the real world: a simulation in patients with a history of myocardial infarction from the HEYMANS register
Ray, K, Bridges, I, Bruckert, E, Perrone-Filardi, P, Annemans, L, Sibartie, M, Dhalwani, N, Villa, G
Published in European heart journal (12.10.2021)
Published in European heart journal (12.10.2021)
Get full text
Journal Article
Evolocumab use in Europe: clinical guidelines vs. reimbursement thresholds – results from the HEYMANS study
Ray, K K, Bruckert, E, Filardi, P, Ebenbichler, C, Vogt, A, Bridges, I, Sibartie, M, Dhalwani, N N
Published in European heart journal (12.10.2021)
Published in European heart journal (12.10.2021)
Get full text
Journal Article